raw data.

Best Practices for Summary Tables:

Summary tables condense large datasets into meaningful summaries. Examples include demographics, adverse events, or efficacy endpoints. To improve clarity:

• Use consistent formats across all tables
• Place titles and footnotes directly above and below tables
• Include descriptive titles (e.g., “Table 5.1: Summary of Adverse Events by SOC and Preferred Term”)
• Keep column headers consistent with statistical analysis plan (SAP)
• Highlight statistically significant results using bold or shading

Use monospace fonts and horizontal lines to separate headers from data rows for better readability. Don’t forget footnotes to define abbreviations or calculation methods.

Guidelines for Data Listings:

Listings show raw subject-level data such as vital signs, lab tests, or AE logs. These usually go into appendices. While they are extensive, they should follow rules for consistency:

• One line per subject event or entry
• Include subject ID and treatment group on every row
• Standardize date and time formats
• Maintain sequence order (chronological or by subject)

For ease of navigation, provide bookmarks in the PDF format. These practices help in compliance with GMP documentation and submission standards.

Effective Use of Graphs and Figures:

Graphs are not mandatory per ICH E3 but are recommended for better visual comprehension. Suitable areas for graphs include:

• Time-course plots for pharmacokinetics (PK)
• Bar graphs for AE frequency
• Box plots for lab parameters
• Kaplan-Meier curves for survival data

Ensure that graphs are:

• Accompanied by clear legends
• Labelled with axis titles and units
• Formatted using grayscale or contrasting colors (especially for printing)
• Exported at high resolution (300 DPI or vector format)

Graphs should support—not replace—table data. Always present the corresponding numeric data in tables to maintain regulatory compliance.

Integrating Data into the Body of the CSR:

Data should not just sit in appendices. In the main report:

• Introduce key findings before showing tables
• Summarize patterns or anomalies
• Interpret the data (don’t just restate it)
• Cross-reference table or listing numbers (e.g., “See Table 12.3.1”)

Use consistent terminology between the protocol, statistical analysis plan, and CSR. You may refer to Pharma SOP templates for internal standards on terminology and formatting.

Tools for CSR Data Presentation:

Common software tools include:

• SAS for generating tables and listings
• GraphPad Prism or R for generating high-quality plots
• MS Word and Adobe Acrobat for document assembly
• QC tools for proofreading (PerfectIt, eCTD viewers)

Incorporate a validation step using CSV validation protocol where applicable, especially for computer-generated listings.

Quality Control and Data Accuracy:

Each data element should pass through a QC cycle:

1. Initial data generation by statistician
2. Internal QC by second reviewer
3. Cross-check against source (e.g., SDTM, ADaM datasets)
4. Final formatting and placement in CSR

Document this process as per your SOP to ensure audit readiness.

Common Mistakes to Avoid:

• Inconsistent use of decimal places
• Unlabeled or misplaced footnotes
• Graphs with missing axis labels
• Data mismatches between tables and listings
• Using color coding without textual explanation

Even small formatting errors can lead to major regulatory queries. Always double-check every figure and table reference.

Review and Finalization Checklist:

Before finalizing your CSR:

• Verify table and listing numbers match the TOC
• Review cross-references to ensure they are not broken
• Confirm consistency with SAP outputs
• Perform peer review of all figures and tables
• Validate any data used from Stability testing protocols to ensure consistency

Incorporating a checklist ensures comprehensive review and avoids surprises during audits or regulatory inspections.

Conclusion:

Presenting data effectively in a Clinical Study Report is more than just placing tables and graphs. It’s about organizing data logically, visually, and compliantly to meet ICH E3 and global regulatory expectations. Following the best practices outlined here will ensure your CSR is review-friendly, data-rich, and aligned with high standards of pharmaceutical compliance.

Whether you’re a seasoned medical writer or a new clinical scientist, mastering CSR data presentation is a vital skill. Use these techniques as a foundation to create impactful, credible reports that pass regulatory scrutiny with ease.